On November eighth, 2023, Eli Lilly and Company’s Zepbound (tirzepatide) received FDA approval as the primary and only approved medication to activate two incretin hormone receptors to focus on an underlying reason for extra weight.
The brand new medication is supposed for adults with a Body Mass Index (BMI) of 30 kg/m2 or higher, or individuals with a BMI of 27 kg/m2 or greater who’ve medical conditions equivalent to hypertension, high blood lipids or type 2 diabetes (T2D).
Zepmound was approved based on results from phase three of the SURMOUNT-1 and SURMOUNT-2 trials. In SURMOUNT-1, participants lost a median of 48 lbs when taking the best dose (15 mg), and a median of 34 lbs on the bottom dose of 5 mg.
Possible unintended effects of Zepbound included:
- Diarrhea or constipation
- Vomiting and upset stomach
- Reactions on the injection site
Usually, nausea, vomiting and diarrhea were attributable to higher doses but typically decreased with time.
The connection between T2D and weight
Weight and T2D are related in several ways. Being obese increases the chance of developing T2D, though it doesn’t directly cause it. T2D typically develops after years of insulin resistance, where your body doesn’t process insulin appropriately.
Obesity is one in all the most important risk aspects in the event of metabolic diseases—including T2D. As obesity makes your body less sensitive to insulin, it’s harder to your body to control your blood sugar levels (BGLs). Research shows that 80 to 90% of adults with T2D even have higher body weights or live with obesity.
The impact of Mounjaro
Last 12 months Lilly released Mounjaro, which is an injectable medication that helps treat T2D.
Mounjaro studies resulted in reduced A1c, weight reduction, a decreased risk of hypoglycemia compared to other medications and reductions in triglycerides and cholesterol.
Studies have also shown that Mounjaro helped bring BGLs into the goal range and decreased the variability of BGL spikes. From the success of Mounjaro helping individuals with diabetes reach their goals, including weight reduction, it gained interest by those that don’t have diabetes.
For a lot of without diabetes, the wait for Zepbound has been in anticipation. This approval is a giant step for helping those with higher weight reach their weight management goals after trying other medications or lifestyle changes with no success.
Each Mounjaro and Zepbound medication are supposed to be used together with a reduced-calorie food regimen and physical activity.
The best way to access Mounjaro and Zepbound
A standard barrier to any latest medication access is cost. There may be a savings program available for Mounjaro and Zepbound; nevertheless, it’s also essential to confer with your doctor so as to get a prescription first.
Zepbound is predicted to be available within the U.S. by the tip of 2023 in six doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg), but continues to be under regulatory review for weight management in Europe, China, the UK and a number of other additional markets.
To receive updates about Zepbound join here.
This content mentions Lilly, an energetic partner of Beyond Type 1.
News coverage by the Beyond Type 1 team is operated independently from any content partnerships. Beyond Type 1 maintains full editorial control of all content published on our platforms.